Otsuka, Click’s Rejoyn Depression DTx Launches In U.S.   

Otsuka Pharmaceutical and Click Therapeutics launched U.S. sales of Rejoyn, a prescription digital therapeutic (DTx) authorized by the FDA for the treatment of major depressive disorder (MDD) symptoms. The Rejoyn app is available in mobile app stores; a prescription is required to unlock the app. ;

Rejoyn, a six-week treatment program, is intended to reduce MDD symptoms. It aims to enhance cognitive control of emotion through a combination of;clinically validated;cognitive emotional training exercises for the brain and brief therapeutic lessons. Rejoyn was cleared by the FDA earlier in 2024 to treat MDD symptoms as . . .